Institution Directory

Clinical trials at Massachusetts General Hospital

Sites in Boston, MA

Institution pages show live ClinicalTrials.gov records that list this campus as a study site, whoever sponsors them. They do not rate, rank, or describe the institution.

ClinicalTrials.gov public records Last synced Oct 22, 2026, 1:11 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials

1487

Shown on this page

Current sort

Live official records

Conditions: Kidney Failure, Kidney Transplant; Complications, Chimera
Interventions: Bone Marrow Transplant, Peripheral Blood Stem Cell Collection, Fludarabine, Cyclophosphamide, Rituximab, Siplizumab; Other · Procedure · Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2032
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Renal Failure
Interventions: Rituximab, Fludarabine, Cyclophosphamide, Thymic irradiation and Siplizumab, Combined bone marrow and kidney transplant; Drug · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Recurrent Ovarian Cancer, Recurrent Fallopian Tube Cancer, Recurrent Primary Peritoneal Cancer, Recurrent Endometrial Cancer, Endometrial Cancer, Low-grade Serous Ovarian Cancer
Interventions: Ubamatamab, Cemiplimab, Sarilumab, Tocilizumab; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 890 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 12
States / cities: Birmingham, Alabama • Boston, Massachusetts • Rochester, Minnesota + 7 more

Conditions: Multiple Myeloma
Interventions: JNJ-79635322; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 168 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 30
States / cities: Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 24 more

Conditions: Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation
Interventions: Combined Kidney/Bone Marrow Transplant, Donation of Kidney / Bone Marrow, Conditioning Regimen (Rituxan, Siplizumab (or ATGAM), Cyclophosphamide, Tegoprubart); Procedure · Drug
Lead sponsor: Tatsuo Kawai, MD, PhD; Other
Eligibility: 18 Years to 65 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Carcinoma, Hepatocellular, Liver Cancer, Liver Cirrhosis, Hepatitis B
Interventions: GALAD, Liver Ultrasound with or without AFP; Diagnostic Test
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years to 85 Years
Enrollment: 5,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2034
U.S. locations: 19
States / cities: Los Angeles, California • Redwood City, California • Roseville, California + 14 more

Conditions: Leukemia, Myeloid, Acute
Interventions: Bleximenib, Venetoclax (VEN), Azacitidine (AZA), Cytarabine, Daunorubicin or Idarubicin; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 12 Years and older
Enrollment: 196 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 7
States / cities: Birmingham, Alabama • Duarte, California • Boston, Massachusetts + 4 more

Conditions: Acute Leukemia
Interventions: Bleximenib; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 2 Years and older
Enrollment: 420 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2030
U.S. locations: 26
States / cities: Duarte, California • Orange, California • San Francisco, California + 20 more

Conditions: Multiple Myeloma
Interventions: Cilta-cel; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 295 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2041
U.S. locations: 28
States / cities: Phoenix, Arizona • Duarte, California • San Francisco, California + 21 more

Conditions: Sleep Deprivation, Critical Illness, Sleep-Wake Disorders, Bundle Care, Implementation Science, Delirium
Interventions: Nighttime noise & light reduction, Clustering patient-care interactions, Non-pharmacologic sleep aids, Daytime light exposure, Encourage out-of-bed activity, Medication management to support nighttime sleep; Behavioral · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older
Enrollment: 62,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 7
States / cities: La Jolla, California • San Francisco, California • Orlando, Florida + 4 more

Conditions: Wilson Disease
Interventions: UX701, Standard of Care (SOC); Genetic · Drug
Lead sponsor: Ultragenyx Pharmaceutical Inc; Industry
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2034
U.S. locations: 12
States / cities: Los Angeles, California • Redwood City, California • Sacramento, California + 9 more

Conditions: Parkinson Disease (PD), PARKINSON DISEASE (Disorder), Gut Microbiome, Gut Microbiota, Prodromal Parkinsons Disease
Interventions: Not listed
Lead sponsor: Duke University; Other
Eligibility: 21 Years to 80 Years
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 7
States / cities: Stanford, California • Chicago, Illinois • Boston, Massachusetts + 3 more

About this Massachusetts General Hospital institution page

What this page lists: ClinicalTrials.gov records that list Massachusetts General Hospital in Boston, MA as a study site, whoever sponsors them, among recruiting, not yet recruiting, and active not recruiting trials.
Site status: A study's overall status can differ from this site's status. Sites marked withdrawn, terminated, or completed are not counted here. Each record shows the status listed for this site when the official record provides one.
Where the data comes from: Records are sourced from the official ClinicalTrials.gov public API. Each result links back to the official study page, which is the source of truth for eligibility, enrollment, and contact information.
What this page does not do: No medical advice, eligibility judgments, ranking of trials, or AI-generated medical summaries. This page does not rank or rate institutions.

Clinical trials at Massachusetts General Hospital

Filter and sort this campus

Live official records

Delayed Tolerance Through Mixed Chimerism

Renal Allograft Tolerance Through Mixed Chimerism - SMC/MGH

Study of REGN4018 (Ubamatamab) Administered Alone or in Combination With Cemiplimab in Adult Patients With Recurrent Ovarian Cancer or Other Recurrent Mucin-16 Expressing (MUC16+) Cancers

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

Tolerance Through Mixed Chimerism (Sip-Tego)

National Liver Cancer Screening Trial

A Study of Bleximenib in Combination With Acute Myeloid Leukemia (AML) Directed Therapies

A Phase 1/2 Study of Bleximenib in Participants With Acute Leukemia (cAMeLot-1)

A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel

Sleep Harmonization Via Bundled Team-Based Interventions in the ICU

A Phase 1/2/3 Study of UX701 Gene Therapy in Adults With Wilson Disease

GBPDC: Gut-Brain in PD Consortium Master Protocol

About this Massachusetts General Hospital institution page